Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside?
Guedan S, Luu M, Ammar D, Barbao P, Bonini C, Bousso P, Buchholz CJ, Casucci M, De Angelis B, Donnadieu E, Espie D, Greco B, Groen R, Huppa JB, Kantari-Mimoun C, Laugel B, Mantock M, Markman JL, Morris E, Quintarelli C, Rade M, Reiche K, Rodriguez-Garcia A, Rodriguez-Madoz JR, Ruggiero E, Themeli M, Hudecek M, Marchiq I. Guedan S, et al. J Immunother Cancer. 2022 May;10(5):e003487. doi: 10.1136/jitc-2021-003487. J Immunother Cancer. 2022. PMID: 35577501 Free PMC article. Review.
Immobilizing A Moving Target: CAR T Cells Hit CD22.
Guedan S, Delgado J. Guedan S, et al. Clin Cancer Res. 2019 Sep 1;25(17):5188-5190. doi: 10.1158/1078-0432.CCR-19-1649. Epub 2019 Jul 2. Clin Cancer Res. 2019. PMID: 31266831
Analysis of CAR-Mediated Tonic Signaling.
Calderon H, Mamonkin M, Guedan S. Calderon H, et al. Among authors: guedan s. Methods Mol Biol. 2020;2086:223-236. doi: 10.1007/978-1-0716-0146-4_17. Methods Mol Biol. 2020. PMID: 31707680
Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies.
Glez-Vaz J, Azpilikueta A, Olivera I, Cirella A, Teijeira A, Ochoa MC, Alvarez M, Eguren-Santamaria I, Luri-Rey C, Rodriguez-Ruiz ME, Nie X, Chen L, Guedan S, Sanamed MF, Perez Gracia JL, Melero I. Glez-Vaz J, et al. Among authors: guedan s. J Immunother Cancer. 2022 Mar;10(3):e003532. doi: 10.1136/jitc-2021-003532. J Immunother Cancer. 2022. PMID: 35236742 Free PMC article.
Genome Editing in Engineered T Cells for Cancer Immunotherapy.
Bonini C, Chapuis AG, Hudecek M, Guedan S, Magnani C, Qasim W. Bonini C, et al. Among authors: guedan s. Hum Gene Ther. 2023 Sep;34(17-18):853-869. doi: 10.1089/hum.2023.128. Hum Gene Ther. 2023. PMID: 37694593 Review.
Genome Editing in CAR-T Cells Using CRISPR/Cas9 Technology.
Andreu-Saumell I, Rodriguez-Garcia A, Guedan S. Andreu-Saumell I, et al. Among authors: guedan s. Methods Mol Biol. 2024;2748:151-165. doi: 10.1007/978-1-0716-3593-3_12. Methods Mol Biol. 2024. PMID: 38070114
36 results